Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors

Francesco Fazio, Luana Lionetto, Martina Curto, Luisa Iacovelli, Caroline S. Copeland, Stuart A. Neale, Valeria Bruno, Giuseppe Battaglia, Thomas E. Salt, Ferdinando Nicoletti

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders. This article is part of the Special Issue entitled ‘The Kynurenine Pathway in Health and Disease’.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalNeuropharmacology
Volume112
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Kynurenine
Metabotropic Glutamate Receptors
3-Hydroxyanthranilic Acid
Vesicular Glutamate Transport Proteins
Aryl Hydrocarbon Receptors
Brain
Dimerization
Nervous System Diseases
Synaptic Transmission
Tryptophan
Psychiatry
Immune System
Schizophrenia
Biomarkers
xanthurenic acid
cinnabarinic acid
Health

Keywords

  • Cinnabarinic acid
  • Metabotropic glutamate receptors
  • Neuroinflammation
  • Schizophrenia
  • Xanthurenic acid

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Cinnabarinic acid and xanthurenic acid : Two kynurenine metabolites that interact with metabotropic glutamate receptors. / Fazio, Francesco; Lionetto, Luana; Curto, Martina; Iacovelli, Luisa; Copeland, Caroline S.; Neale, Stuart A.; Bruno, Valeria; Battaglia, Giuseppe; Salt, Thomas E.; Nicoletti, Ferdinando.

In: Neuropharmacology, Vol. 112, 01.01.2017, p. 365-372.

Research output: Contribution to journalReview article

Fazio, F, Lionetto, L, Curto, M, Iacovelli, L, Copeland, CS, Neale, SA, Bruno, V, Battaglia, G, Salt, TE & Nicoletti, F 2017, 'Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors', Neuropharmacology, vol. 112, pp. 365-372. https://doi.org/10.1016/j.neuropharm.2016.06.020
Fazio, Francesco ; Lionetto, Luana ; Curto, Martina ; Iacovelli, Luisa ; Copeland, Caroline S. ; Neale, Stuart A. ; Bruno, Valeria ; Battaglia, Giuseppe ; Salt, Thomas E. ; Nicoletti, Ferdinando. / Cinnabarinic acid and xanthurenic acid : Two kynurenine metabolites that interact with metabotropic glutamate receptors. In: Neuropharmacology. 2017 ; Vol. 112. pp. 365-372.
@article{3584c09ac9084d85aca69fbd40c34f8b,
title = "Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors",
abstract = "Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders. This article is part of the Special Issue entitled ‘The Kynurenine Pathway in Health and Disease’.",
keywords = "Cinnabarinic acid, Metabotropic glutamate receptors, Neuroinflammation, Schizophrenia, Xanthurenic acid",
author = "Francesco Fazio and Luana Lionetto and Martina Curto and Luisa Iacovelli and Copeland, {Caroline S.} and Neale, {Stuart A.} and Valeria Bruno and Giuseppe Battaglia and Salt, {Thomas E.} and Ferdinando Nicoletti",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.neuropharm.2016.06.020",
language = "English (US)",
volume = "112",
pages = "365--372",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Cinnabarinic acid and xanthurenic acid

T2 - Two kynurenine metabolites that interact with metabotropic glutamate receptors

AU - Fazio, Francesco

AU - Lionetto, Luana

AU - Curto, Martina

AU - Iacovelli, Luisa

AU - Copeland, Caroline S.

AU - Neale, Stuart A.

AU - Bruno, Valeria

AU - Battaglia, Giuseppe

AU - Salt, Thomas E.

AU - Nicoletti, Ferdinando

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders. This article is part of the Special Issue entitled ‘The Kynurenine Pathway in Health and Disease’.

AB - Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders. This article is part of the Special Issue entitled ‘The Kynurenine Pathway in Health and Disease’.

KW - Cinnabarinic acid

KW - Metabotropic glutamate receptors

KW - Neuroinflammation

KW - Schizophrenia

KW - Xanthurenic acid

UR - http://www.scopus.com/inward/record.url?scp=84977126075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977126075&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.06.020

DO - 10.1016/j.neuropharm.2016.06.020

M3 - Review article

C2 - 27342123

AN - SCOPUS:84977126075

VL - 112

SP - 365

EP - 372

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -